Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of SHR-A1811(sc) injection, which will be conducted in patients with advanced solid tumors [1][2]. Group 1: Company Information - Hengrui Medicine's subsidiary, Suzhou Sediya Biopharmaceutical Co., Ltd., is responsible for the clinical trial of SHR-A1811(sc) injection [1]. - The clinical trial application for SHR-A1811(sc) injection was accepted on September 10, 2025, and has met the requirements for drug registration [2]. Group 2: Drug Information - The drug SHR-A1811(sc) is an injectable formulation intended for use in clinical trials [2]. - The approval allows for the drug to be tested specifically in patients with advanced solid tumors [2].